Objective To investigate the protective effect of magnesium isoglycyrrhizinate( Mg IG) in rats with acute liver failure induced by D- galactosamine( D- Gal N) and related mechanisms. Methods A total of 90 Sprague- Dawley rats were randomly divided into normal group( group A,n = 10),model group( group B,n = 20),low- dose Mg IG group( group C,n = 20),medium- dose Mg IG group( group D,n = 20),and high- dose Mg IG group( group E,n = 20). The rats in group A received intraperitoneal injection of the same volume of normal saline,and those in the other groups received single intraperitoneal injection of 10% D- Gal N. At 30 minutes after establishment of the model,the rats in groups C,D,and E received tail vein injection of Mg IG injection( 25,50,and 100 mg / kg). At 24 and 48 hours after establishment of the model,HE staining was performed to observe the pathological changes in the liver,and serum was collected to measure the levels of liver function parameters [alanine aminotransferase( ALT),aspartate aminotransferase( AST),total bilirubin( TBil),and albumin( Alb) ],proinflammatory factors [tumor necrosis factor- α( TNFα),interleukin- 1β( IL- 1β),and interferon-γ( IFNγ) ],and anti- inflammatory factors [interleukin 4( IL- 4),interleukin- 10( IL- 10),and transforming growth factor β( TGFβ) ]in rats. The one- way analysis of variance was applied for comparison between multiple groups,and the Student- Newman-Keuls test was applied for comparison between any two groups. Results The serum levels of ALT,AST,TBil,and Alb showed significant differences across the five groups( F = 74. 6,108. 9,25. 1,and 58. 4,all P < 0. 05); compared with group A,group B had significant increases in the serum levels of ALT,AST,and TBil and a significant reduction in the serum level of Alb( all P < 0. 05); compared with group B,groups C,D,and E had significant reductions in the serum levels of ALT,AST,and TBil and a significant increase in the serum level of Alb,and these parameters showed the most significant changes in group E( all P < 0. 05). The serum levels of TNFα,IL- lβ,IFNγ,IL-4,IL- 10,and TGFβ showed significant differences across the five groups( F = 75. 1,58. 9,25. 4,43. 6,66. 4,and 86. 8,all P <0. 05); compared with group A,group B had significant increases in the serum levels of TNFα,IL- lβ,IFNγ,IL- 4,IL- 10,and TGFβ( all P < 0. 05); compared with group B,groups C,D,and E had significant reductions in the serum levels of TNFα,IL- lβ,and IFNγand significant increases in the serum levels of IL- 4,IL- 10,and TGFβ,and these parameters showed the most significant changes in group E( all P < 0. 05). Conclusion Mg IG can reduce inflammatory response through reducing proinflammatory factors and increasing anti- inflammatory factors,and thus exert protective effect on rats with ALF.
Cox比例风险模型结果显示：在校正年龄、性别、HDL-C、TG、ALT、Hs-CRP、家庭收入、受教育程度后，CHS每增加1分，NAFLD的发病风险比为0.73(0.72~0.74)。CHS与NAFLD发病风险的剂量-反应关系，RCS结果表明(取25%、50%和75% 3个截点)：CHS连续型变量与NAFLD呈非线性关系(P＜0.05)。将CHS的不同分组代入模型，校正相同的混杂因素后，以Q1组为对照组，Q2组、Q3组、Q4组发生NAFLD的风险逐渐降低(P for trend＜0.05)，Q2组发病风险比为0.78(0.74~0.81)，Q 3组发病风险比为0.57(0.54~0.59)，Q4组发病风险比为0.38(0.36~0.41)。在男女性及年龄的分层分析中，也得到了类似的结果(P for trent＜0.05)(表 2)。
表
2
心血管健康评分影响NAFLD发病的Cox风险比例模型
项目
例数
发病例数
发病率(/千人年)
HR(95%CI)
P值
总体
Q1组
10 057
4104
77.88
Q2组
17 732
5956
61.33
0.78(0.74~0.81)
＜0.001
Q3组
10 321
2737
46.37
0.57(0.54~0.59)
＜0.001
Q4组
12 401
2468
33.69
0.38(0.36~0.41)
＜0.001
性别
＜0.0011)
男
Q1组
9336
3655
73.94
Q2组
14 723
4492
54.84
0.77(0.73~0.80)
＜0.001
Q3组
7492
1725
39.79
0.57(0.53~0.60)
＜0.001
Q4组
6402
1097
28.92
0.52(0.39~0.45)
＜0.001
女
Q1组
721
449
137.57
Q2组
3009
1464
96.32
0.79(0.71~0.88)
＜0.001
Q3组
2829
1012
64.65
0.56(0.50~0.63)
＜0.001
Q4组
5999
1371
38.81
0.37(0.33~0.42)
＜0.001
年龄
＜0.0011)
≤45岁
Q1组
3106
1164
67.79
Q2组
5584
1773
55.02
0.83(0.77~0.90)
＜0.001
Q3组
3751
890
39.91
0.58(0.53~0.64)
＜0.001
Q4组
6192
1016
27.14
0.37(0.34~0.41)
＜0.001
＞45岁
Q1组
6951
2940
82.75
Q2组
12 148
4183
64.46
0.76(0.72~0.79)
＜0.001
Q3组
6570
1847
50.29
0.56(0.53~0.60)
＜0.001
Q4组
6209
1452
40.54
0.42(0.39~0.45)
＜0.001
注：模型校正了年龄、性别、HDL-C、TG、ALT、Hs-CRP、家庭收入、受教育程度。1)P for interaction＜0.001。
[1]ZHU LY.The Progress of magnesuim isoglycyrrhizinate in clinical research[J].J Hainan Med Coll,2013,19(12):1776-1780.(in Chinese)朱礼尧.浅述异甘草酸镁临床研究进展[J].海南医学院学报,2013,19(12):1776-1780.
[2]QIAO Y,HAO RL,TANG ZQ.Clinical study on telbivudine and magnesium isoglycyrrhizinate in treatment of severe hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2015,9(5):670-673.(in Chinese)乔英,郝润来,唐中权.替比夫定和异甘草酸镁治疗重型乙型肝炎的临床研究[J/CD].中华实验和临床感染病杂志:电子版,2015,9(5):670-673.
[3]GU X,DONG LP,LIU CY,et al.Protective effect of magnesium isogiycyrrhizinate on acute hepatic injury induced by CCl4 in Mice[J].China Pharmacist,2009,12(1):37-39.(in Chinese)顾新,董丽萍,刘宇宸,等.异甘草酸镁对急性四氯化碳肝损伤小鼠保护作用的研究[J].中国药师,2009,12(1):37-39.
[4]XIE YF,LIU JG,LIU Q,et al.Protective effect of magnesium isogiycyrrhizinate on acute alcoholic liver injury in mice[J].J Pract Med,2010,26(3):381-383.(in Chinese)谢议凤,刘建国,刘庆,等.异甘草酸镁对小鼠急性酒精性肝损伤的保护作用[J].实用医学杂志,2010,26(3):381-383.
[5]JING XZ,LIU J,QIAN H.The therapeutic efficacy of magnesium isoglycyrrhizinate on rats with non alcoholic steatohepatitis[J].J Clin Hepatol,2011,27(3):295-297.(in Chinese)经小珍,刘竞,钱海.异甘草酸镁治疗大鼠非酒精性脂肪性肝炎及其作用机制[J].临床肝胆病杂志,2011,27(3):295-297.
[6]ZHAO J,LIU HH,TAN BY.Experimental study of magnesium isog Iycyrrhizinate treatment on liver injury in severe a cute pancreatitis[J].J Med Res,2014,43(11):147-149.(in Chinese)赵建,刘红辉,谭波宇.异甘草酸镁对重症急性胰腺炎肝损伤治疗作用的实验研究[J].医学研究杂志,2014,43(11):147-149.
[7]HUANG JJ,LI XP,CHEN XY,et al.Expression of intestinal defensin-5,soluble phospholipase A2 and lysozyme and the relation to bacterial translocation in rat models of acute liver failure[J].Chin J Hepatol,2014,22(12):138-143.(in Chinese)黄娟君,李小鹏,程晓宇,等.急性肝衰竭大鼠模型肠道防御素-5、分泌型磷脂酶A2和溶菌酶表达变化及与细菌移位的关系[J].中华肝脏病杂志,2014,22(12):138-143.
[8] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病分会,感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.
[9] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology.Guideline for diagnosis and treatment of liver failure(2012 Version)[J].Chin J Clin Infect Dis,2012,5(6):321-330.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组,肝病分会重型肝炎与人工肝学组.肝衰竭诊疗指南(2012版)[J].中华临床感染病杂志,2012,5(6):321-330.
[10]LUCIA AP,CHARALAMBOS GA,QUENTIN MA,et al.Role of monocytes and macrophages in experimental and human acute liver failure[J].World J Gastroenterol,2010,16(15):1811-1819.
[11]CHEN N,ZHANG LL,XUE GR,et al.An initial study on the imbalance of pro-inflammatory cytokine and anti-inflammatory cytokine in patients with acute liver failure induced by HBV[J].Guangdong Med J.2012,33(8):1150-1152.(in Chinese)程娜,张伦理,徐国荣,等.HBV感染的急性肝衰竭患者促炎因子及抗炎因子失衡的初步研究[J].广东医学,2012,33(8):1150-1152.
ZHAO DN, LIU Q, LIANG HJ, et al. Effect of ideal cardiovascular health metrics on the incidence rate of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38(1): 124-128. DOI: 10.3969/j.issn.1001-5256.2022.01.019.
ZHAO DN, LIU Q, LIANG HJ, et al. Effect of ideal cardiovascular health metrics on the incidence rate of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38(1): 124-128. DOI: 10.3969/j.issn.1001-5256.2022.01.019.
下载:
DownLoad: